Systemic Corticosteroid

Prednisolone, a cornerstone glucocorticoid in modern medicine, evolved from mid-20th-century breakthroughs in adrenal steroid research that transformed the treatment of inflammatory disease. Early therapeutic use of adrenal extracts for Addison’s disease dates back to the 19th century, but a major advance occurred when Edward Kendall isolated cortisone in the 1930s, and Philip Hench demonstrated its dramatic benefit in rheumatoid arthritis in 1948–49—work that earned the 1950 Nobel Prize. Building on this foundation, microbial modification techniques in 1950 enabled the synthesis of prednisone and prednisolone, compounds with a Δ1 double bond that conferred greater anti-inflammatory potency and improved oral efficacy compared with cortisone. Their clinical success stimulated the development of successive generations of corticosteroids, including topical hydrocortisone, fluorinated agents such as betamethasone, and later molecules like budesonide, broadening therapeutic applications to asthma, autoimmune disorders, transplantation, and allergic disease. In parallel, steroid chemistry also led to the development of anabolic agents following testosterone isolation in 1935, which later expanded beyond medical use into competitive athletics and ultimately prompted regulatory controls, highlighting both the transformative therapeutic value and the societal complexities of steroid pharmacology. Gordon and McLean in 1950 introduced the use of corticosteroid and ACTH for ophthalmic use. The first rational use of prednisone and prednisolone for ocular inflammatory diseases was described by Gordon in 1956 where topical steroid was found to be efficacious in anterior segment disease and systemic steroid was preferred for posterior disease.

The table below ennlists common corticosteroids in ophthalmology, which are used systemically (oral/IV) or locally (topical/periocular/intravitreal) for uveitis and inflammation, with relative potencies standardized to hydrocortisone (assigned a value of 1). Hydrocortisone serves as the universal reference because it is the natural endogenous glucocorticoid produced by the adrenal cortex, providing a baseline with balanced anti-inflammatory (glucocorticoid) and sodium-retaining (mineralocorticoid) effects; this allows precise comparisons of synthetic analogs’ enhanced potency, duration, and selectivity to guide dosing equivalents and minimize side effects like fluid retention.Potencies reflect anti-inflammatory strength relative to hydrocortisone=1, while equivalent doses approximate the mg needed to match 20 mg hydrocortisone’s daily effect for safe systemic conversions in clinical practice. (1),(2)

Systemic Corticosteroids: Classification, Mechanism, and Clinical Implications

Systemic corticosteroids are classified based on three main features: their anti-inflammatory potency, their mineralocorticoid (salt-retaining) effect, and the duration for which they suppress the hypothalamic–pituitary–adrenal (HPA) axis. Potency is measured relative to hydrocortisone and helps determine equivalent dosing. Structural modifications in newer steroids are aimed at increasing anti-inflammatory strength while reducing unwanted mineralocorticoid effects such as sodium and water retention. The anti-inflammatory and metabolic (carbohydrate-related) effects occur through activation of the same glucocorticoid receptor, whereas sodium-retaining effects are mediated through a separate mineralocorticoid receptor—explaining why these actions are not always proportional. (3) Corticosteroids are also described as short-, intermediate-, or long-acting based on how long they suppress the HPA axis. Because they act inside cells and influence gene transcription, their biological effects often last longer than their measurable blood levels. Hydrocortisone is less suitable for systemic use due to significant mineralocorticoid activity. (1), (2) Highly potent agents such as dexamethasone and betamethasone have minimal mineralocorticoid effects but are generally reserved for short-term use. Deflazacort was developed with the hope of reducing steroid-induced bone loss, but in practice it has not shown clear clinical advantages and is not widely used.

Mechanism of Action of Corticosteroids

(1) Molecular Action: Gene-Level Modulation

• Corticosteroids enter the cell and bind to the glucocorticoid receptor in the cytoplasm.
• The drug–receptor complex moves into the nucleus.
• It switches specific genes on or off.
• This alters protein production, leading to reduced inflammation.
• Because the action occurs at the gene level, clinical effects last longer than the drug’s measurable blood levels.

In simple terms: corticosteroids “reprogram” inflammatory cells, rather than just blocking inflammation temporarily.

(2) Effects on the Immune System

(3) Functional Immunologic Effects

• Reduced bactericidal activity.
• Suppressed delayed hypersensitivity reactions.
• Altered immediate hypersensitivity responses.
• Decreased lymphokine (cytokine) production.

(4) Effects on Blood Vessels and Tissues

Hypothalmic-pituitary-adrenal axis and Corticosteroid:

• The adrenal cortex is regulated by the hypothalamic–pituitary–adrenal (HPA) axis, a hormonal feedback system that finely controls cortisol production and helps maintain normal body function.
• Timing of steroid dosing matters:(6) (7)
  • A morning dose of less than 15 mg of prednisolone is unlikely to significantly suppress the HPA axis.
  • Even 5 mg taken in the evening can suppress the early morning cortisol surge.
• With long-term oral corticosteroid therapy, recovery of the HPA axis may take 6–12 months after tapering (6) (7)
  • If treatment duration is less than 3 weeks, significant suppression is unlikely.
• The anti-inflammatory effect of prednisolone lasts 12–36 hours (8)
  • This is the basis of alternate-day therapy, where a double dose is taken on one day and none on the next, aiming to maintain efficacy while reducing adrenal suppression.

Pharmacokinetics of Oral Corticosteroid:

After oral intake, most glucocorticoids are rapidly absorbed, primarily from the upper jejunum within about 30 minutes, achieving approximately 90% bioavailability and peak plasma concentrations at 30 minutes to 2 hours. Prednisolone and methylprednisolone exhibit plasma half-lives of 2-3 hours, though biological anti-inflammatory effects persist much longer (12-36 hours); these drugs undergo hepatic metabolism (mainly via CYP3A4) into inactive metabolites, which are then renally excreted as glucuronides and sulfates. (9),(10)

Systemic corticosteroids such as oral prednisolone reach meaningful intraocular levels within a few hours, even in the absence of active inflammation, which supports their use in posterior uveitis. Experimental data show that after an oral dose, plasma levels peak at about 1 hour, aqueous levels reach roughly 70% of plasma concentrations, and measurable drug penetrates the vitreous within 4–10 hours at potentially therapeutic levels. (13) Similar pharmacokinetic patterns have been observed with dexamethasone in humans. In practical terms, this confirms that oral prednisolone is effective for treating posterior segment inflammation through systemic therapy.

Prednisolone at a glance

• Prednisolone is the most commonly used oral corticosteroid in ophthalmology.
• It has high oral bioavailability, so absorption is reliable.
• It has an intermediate duration of action (12–36 hours), making dose adjustments easier compared to long-acting agents like dexamethasone (48–52 hours).
• Prednisolone has a high affinity for transcortin (corticosteroid-binding globulin) and competes with cortisol for binding.
• Other synthetic glucocorticoids (e.g., methylprednisolone, dexamethasone, triamcinolone) have little affinity for transcortin; about two-thirds bind weakly to albumin, and one-third remains free in circulation.
• Prednisolone provides strong anti-inflammatory effects with relatively fewer metabolic side effects compared to some other steroids.
• It can be used in patients with liver disease, as it does not require hepatic activation.

Pulse Corticosteroid Therapy:

High-dose intravenous corticosteroids were first reported in 1969, when they were successfully used to prevent renal transplant rejection. Pulse therapy refers to giving very large doses of a drug intermittently over a short period to achieve a rapid and strong therapeutic effect while limiting the side effects associated with prolonged daily therapy. (14) Intravenous pulse steroids, once described as a “big shot”, are particularly useful in severe, sight-threatening intraocular inflammation. (15),(16) They produce a rapid and marked anti-inflammatory response, often more pronounced and longer-lasting than smaller single doses. After intravenous methylprednisolone (IVMP), treatment is usually continued with high-dose oral steroids or an immunosuppressive agent to maintain control.

Drugs and Dose

• Methylprednisolone: 20–30 mg/kg
• Dexamethasone: 4–5 mg/kg

Administration

• The drug is diluted in 150–200 mL of 5% dextrose.
• It is given as a slow intravenous infusion over 2–3 hours.

Methylprednisolone (IV Pulse)

• Intermediate-acting corticosteroid (biological half-life 12–36 hours).
• About 1.25 times more potent than prednisolone. (10)(11)
• Low mineralocorticoid activity (glucocorticoid:mineralocorticoid ratio ~6:1), so minimal sodium and water retention compared to hydrocortisone. (10)(11)
• Usual pulse dose: 500 mg to 1 g IV daily for 3 consecutive days.
• Diluted in 0.9% normal saline or sodium lactate and infused over 30–60 minutes (many prefer slower infusion over 2–3 hours to reduce hemodynamic risk).
• Rapid infusion may increase the risk of cardiovascular instability, so slower administration is safer.
• Believed to have faster cellular penetration than dexamethasone.
• Vitreous levels peak at ~6 hours after a 500 mg IV dose in non-inflamed eyes, and earlier (~2 hours) in eyes with retinal detachment. (14)

Dexamethasone (IV Pulse)

• Fluorinated, long-acting glucocorticoid (biological half-life 36–72 hours).
• Approximately 6–7 times more potent than prednisolone.
• Negligible mineralocorticoid activity, with minimal sodium retention.
• Dose: 4–5 mg/kg, diluted in 150–200 mL of 5% dextrose, infused slowly over 2–3 hours.
• Generally less expensive than methylprednisolone.
• Should be administered in a monitored setting (preferably ICU), similar to methylprednisolone.

Side-effect of Systemic Steroid: 

Systemic corticosteroids are essential for treating severe uveitis and posterior segment inflammation, but their adverse effects are dose- and duration-dependent and require careful monitoring. Short-term complications include suppression of the hypothalamic–pituitary–adrenal axis with risk of adrenal crisis if therapy is stopped abruptly, hyperglycemia, hypertension, mood changes, insomnia, and gastrointestinal irritation. With long-term use (more than three months or doses exceeding 7.5 mg/day of prednisolone equivalent), the risks increase and include osteoporosis and fractures, proximal myopathy, Cushingoid features, dyslipidemia, increased susceptibility to infections including opportunistic pathogens, and avascular necrosis. Ocular adverse effects are particularly relevant and include steroid-induced intraocular pressure elevation, posterior subcapsular cataract, and reactivation of herpetic infections. These aspects will be discussed in detail with evidence-based literature in a separate section of this portal.

Remember Side-effects of Corticosteroid  with mnemonic  CUSHINOID

• Cataracts
• Ulcers (Gastric)
• Skin: striae, thinning, bruising, acne like eruptions
• Hypertension, hirsutism, hyperglycemia
• Infections
• Necrosis, avascular necrosis of the femoral head
• Glycosuria
• Osteoporosis, Obesity 
• Immunosuppression
• Diabetes, Depression

References: